Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Drexel analyst Brian White initiated Snap Inc. (SNAP) with a Buy rating, becoming the second Wall Street research firm to start coverage of the Snapchat parent with a positive recommendation. White calls Snap "a very unique tech company" whose platform "has a cachet with millennials that will be difficult for other platforms to garner" and can be monetized. Additionally, the company's spot as an early pioneer in augmented reality offers the potential for significant monetization opportunities in mobile advertising, contends White, who set a $30 price target on the stock. 2. JMP Securities started coverage of Idera Pharmaceuticals (IDRA) with an Outperform rating, with analyst Michael King saying that the company's nucleic acid therapeutic platform can produce many "promising drug candidates." 3. Ladenburg Thalmann analyst Wangzhi Li started Checkpoint Therapeutics (CKPT) with a Buy rating and $20 price target, calling the company an "under-recognized" investment opportunity "tapping into the combination therapy trend for cancer treatment." 4. Cowen analyst Joseph Giordano initiated Amphenol (APH) with an Outperform rating and a $85 price target, saying near-term estimates look conservative on an organic basis and M&A potential supports a higher valuation. 5. Incyte (INCY) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.